Olaplex reported a Q1 slightly beating the previously guided sales range, and showing a good profitability despite the slower sequential and year-over-year revenues. The company should report its Q2 results soon, and I suggest watching the revenues closely as the 2024 outlook expects sequential improvements. The stock's valuation is becoming more attractive, but due to the high-risk profile regarding the prior PR headwinds and the needed return to growth, I remain neutral.